| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Lisdexamfetamine dimesylate |
| Brand | Tyvense® |
| Indication | For Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate. |
| Assessment Process | |
| Rapid review commissioned | 09/02/2013 |
| Rapid review completed | 28/02/2013 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
